| 摘要: | 
			 
		     | 目的    探究慢性粒细胞白血病肿瘤抗原 66(CML66)在肾肿瘤组织中的表达及其临床意义。 方法    采用免疫组化法 检测 155 例肾癌组织及其癌旁正常肾脏组织、36 例肾血管平滑肌脂肪瘤组织中 CML66 蛋白的表达,分别比较肾癌组织与癌旁正常肾 脏组织、肾血管平滑肌脂肪瘤组织的 CML66 阳性表达率,并分析肾癌组织 CML66 阳性表达率与临床特征的关系。 结果    肾癌组织 中 CML66 阳性表达率为 83.9%,明显高于癌旁正常肾脏组织的 35.5%(P<0.05);但与肾血管平滑肌脂肪瘤组织的 80.6%比较,差异 无统计学意义(P >0.05)。肾癌组织病理分级Ⅲ、Ⅳ级,临床分期Ⅲ、Ⅳ期的 CML66 阳性表达率均分别高于Ⅰ、Ⅱ级 / 期,差异均有统计 学意义(P<0.05)。 结论    CML66 在肾癌组织中高表达有助于明确诊断,可作为评估肾癌病理分级、临床分期的指标,可能对肾癌术 后辅助治疗有一定的参考价值。 | 
			
	         
				| 关键词:  慢性粒细胞白血病肿瘤抗原 66    肾癌    免疫组化 | 
			 
                | DOI: | 
            
                | 分类号: | 
			 
             
                | 基金项目:湖州市科技局公益性重点项目;浙江省医药卫生科技计划骨干人才项目 | 
          |  | 
           
                | Expression  of  CML66  in  renal  carcinoma  and  its  clinical  significance | 
           
			
                | WANG Ning, Zhong Huan, Chen Xiaonong, TANG Jianer, CHEN LI, GAO Jianguo, WANG Rongjiang | 
           
		   
		   
                | the First Affliated Hospital of Huzhou Normal College | 
		   
             
                | Abstract: | 
			
                | Objective    To investigate the expression of CML66 in renal carcinoma and its clinical significance.    Methods The  expression  of  CML66  in  155  samples  of  renal  cell  carcinoma  and  its  adjacent  normal  tissue  and  36  samples  of  renal angiomyolipoma  were  detected  by  immunohistochemical  method.  The  relationship  between  CML66  expression  and  clinical charactenristics of renal cell carcinorma was analyzed.    Results    The positive expression rates of CML66 in renal cell carcinoma was 83.9%, significantly higher than the adjacent normal renal tissue  (P<0.05), but there was no significant difference in CML66 expression between renal cell carcinoma and renal angiomyolipoma  (P >0.05). The positive expression rates of CML66 in renal cell carcinoma of pathological grade and clinical stages Ⅲ/Ⅳ were significantly higher than those in grade Ⅰ/Ⅱ renal carcinoma (P<0.05).    Conclusion    Overexpression of CML66 may be used as an indicator for diagnosis of renal cell carcinoma and evalua- tion of pathological grade and clinical stages. | 
	       
                | Key words:  CML66    Renal tumor    Immunohistochemical method |